San Diego – June 8, 2018 – Cooley advised Iterum Therapeutics plc on its $80 million initial public offering of 6,150,000 ordinary shares. The underwriters have a 30-day option to purchase up to an additional 922,500 shares. Cooley partners Charlie Kim and Alan Hambelton led the team advising Iterum.
Leerink Partners and RBC Capital Markets acted as joint book-running managers for the offering. Guggenheim Securities acted as lead manager. Needham & Company acted as co-manager.
Iterum is an Irish clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. The company’s shares now trade on the Nasdaq Global Market under the symbol “ITRM.”
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.